多家公司，拟中期分红

Group 1: Company Dividend Announcements - Dongfang Yuhong reported a 10.84% decrease in revenue to 13.569 billion yuan and a 40.16% decline in net profit to 564 million yuan for the first half of 2025, proposing a cash dividend of 9.25 yuan per 10 shares [1] - Zhengdan Co. achieved a 3.37% increase in revenue to 1.429 billion yuan and a 120.35% rise in net profit to 630 million yuan, with a proposed cash dividend of 3 yuan per 10 shares [1] - Daodaokuan reported a 1.16% increase in revenue to 2.792 billion yuan and a significant 563.15% increase in net profit to 181 million yuan, proposing a cash dividend of 1.76 yuan per 10 shares [2] Group 2: Major Financial Performance Updates - Sinopec expects a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, representing a decline of 39.5% to 43.7% year-on-year due to factors such as falling international oil prices and intense market competition [3] - Jiejia Weichuang anticipates a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, reflecting a growth of 38.65% to 59.85% year-on-year due to ongoing order fulfillment [6] Group 3: Share Buyback and Corporate Actions - Dajuecheng plans to privatize its subsidiary Dajuecheng Real Estate through a share buyback arrangement, proposing to repurchase shares at 0.62 HKD per share, totaling approximately 2.93 billion HKD [4][5] - Fuanna intends to repurchase shares with a budget of 55.85 million to 104 million yuan for employee stock ownership plans [8] - Aoshikang plans to issue convertible bonds to raise up to 1 billion yuan for high-end printed circuit board projects [8] Group 4: Fundraising and Capital Projects - Sixuan New Materials plans to raise up to 466.1 million yuan through a private placement to fund various projects including a cooling product project in Vietnam [7] - Changhua Chemical aims to raise up to 230 million yuan for its carbon dioxide polyether project [7] Group 5: Corporate Governance Changes - Renfu Pharmaceutical announced a change in its controlling shareholder to招商生命科技 (Wuhan) Co., Ltd., following a board restructuring [8]